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Abstract: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with 
both core symptoms and associated symptoms (eg, irritability, aggression, and comorbidities) 
that affect both the individual and the family/systems around them. There have been recent 
advances in the understanding of the underlying pathophysiology of ASD pertaining to genetics, 
epigenetics, neurological, hormonal, and environmental factors that contribute to the difficul-
ties found in individuals with ASD. With this improved understanding, there has been a shift 
in the application of psychopharmacology in ASD and its related disorders. A literature review 
was conducted to examine research published in the last 5 years between different classes of 
psychotropic medications and ASD. The broad scope of the existing literature for the use of 
conventional medications is summarized and novel medications are discussed.
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Introduction
Autism Spectrum Disorder (ASD) is a complex disorder presenting with deficits in 
social interaction, social communication, and restricted, repetitive patterns of  behaviors, 
interests, or activities. Currently, the Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (DSM-5), and the International Statistical Classification of 
Diseases and Related Health Problems–10th Revision (ICD-10), are the dominant 
diagnostic classifications for this disorder. Pervasive Developmental Disorder – Not 
Otherwise  Specified, as a category, remains less stable with higher degrees of variability 
in diagnosis within categorical and psychodynamic systems.1 The recently developed 
DSM-5 has reconceptualized the spectrum into a broad category – ASD and Social 
 Communication Disorder.2 The diagnostic criteria for autism and its related disorders 
have been collapsed to encompass social communication and social interaction deficits 
as one criteria and restricted, repetitive patterns of behaviors, interests, and activities as 
the other.  However,  controversies remain with regards to categorization and diagnosis. 
This highlights the heterogeneity of the condition and the broader syndrome that we 
are considering when we examine literature on ASD.
ASD research continues to receive considerable attention as the options for success-
ful management are limited. The understanding of the ASD etiology has now progressed 
to encompass genetic, epigenetics, neurological, hormonal, and environmental factors 
that affect outcomes for patients with ASD.3 With the increasing diversity of basic 
sciences and publications relating to pharmacological options for patients with ASD, 
a review of recent literature about the treatment advances in this field is warranted. The 
application of medication in patients with ASD has traditionally targeted associated 





conditions (such as inattention or irritability) that occur in 
the context of ASD, with poor evidence for the core symp-
toms of the condition. However, there are problems with 
the efficacy of medications in this population. In addition, 
children and young people with ASD also have a higher 
likelihood of developing intolerable side effects from the use 
of medications. Nevertheless, recent work has broadened the 
understanding of pharmacological use with newer medica-
tions being tried and studied in this population.
Electronic literature searches were conducted from 
the following sources: MedLine, the Cochrane Library, 
 PsycARTICLES, and PsycINFO. Search terms included, 
but were not limited to, psychotropic medications (anti-
depressants, antipsychotics, mood stabilizers, melatonin, 
glutamate  agonists, oxytocin, and attention deficit hyper-
activity disorder (ADHD) medications (methylphenidate 
[MPH] and atomoxetine) autism, pervasive developmental 
disorders, ASD, and Asperger’s syndrome from 2008 to 
2013 (the last 5 years). The article abstracts obtained from 
the search strategy were perused and eligible articles were 
then retrieved. This article reviews recent evidence support-
ing various medications used in ASD. Evidence from trials 
published prior to 2008 was summarized to provide relevant 
background information.
Scope of medications covered
Conventional pharmacological management in ASD has 
targeted dysfunctional behavioral symptoms that interfere 
with rehabilitative efforts and cause impairment or distress, 
such as aggression, irritability, stereotyped behaviors, anxi-
ety, hyperactivity, and sleep difficulties.4 These pharmaco-
logical agents include the antipsychotics, antidepressants, 
mood stabilizers, and medications targeting inattention and 
hyperactivity. Conventional treatments, with limited recent 
literature, have been summarized to provide an overview and 
will be covered briefly. The focus of this article will be on 
novel treatments with recent interest, including melatonin, 
omega-3 fatty acids, glutamate receptor related medications, 
and oxytocin. These will be described in greater detail.
Antipsychotics
Antipsychotics are the most-studied class of medications in 
the ASD population for efficacy and effectiveness.
Haloperidol has previously been well-studied for efficacy 
and safety.5 However, with concerns of extrapyramidal 
symptoms (EPS),6 typical antipsychotics have been dropped 
in favor of atypical antipsychotics, which have emerged as the 
first-line pharmacologic treatment for behavioral problems 
in ASD.7 As such, recent research in antipsychotic use in ASD 
has been limited to atypical antipsychotics.
While some atypical antipsychotics (such as risperidone 
and aripiprazole) have been better researched, others (such 
as olanzapine, quetiapine, and ziprasidone) have had limited 
data, with a few earlier case studies, open-label studies, or 
small double-blind placebo-controlled studies.8–15 No recent 
studies have focused on these drugs. Concerns with regards 
to adverse effects (such as metabolic side effects) may have 
resulted in limited use.5,7,16
Risperidone is a US Food and Drug Administration (FDA) 
approved antipsychotic for the treatment of symptoms in 
children and adolescents with ASD.7,17 Risperidone is useful 
in the management of behavioral problems, such as irritabil-
ity, aggression, self-injurious behavior, hyperactivity, and 
repetitive behavior.18–21
Recent studies continue to demonstrate the efficacy of 
risperidone,22–24 and focus on its safety and side effects. The 
most common adverse effects are weight gain, increased 
appetite, and somnolence.22–25 Weight gain is a common 
problem and can cause signif icant health problems,22 
while somnolence may more significantly affect treatment 
 discontinuation.23 These side effects are more likely to occur 
in higher doses.24
There is interest in the combination of risperidone with 
other agents. For example, a small randomized controlled 
trial (RCT) showed that adding topiramate to risperidone 
was superior to risperidone alone in reducing irritability, 
stereotypic behavior, and hyperactivity.26 In similar RCTs, 
there was reported benefit in adding pentoxifylline,27 
memantine,28 and celecoxib29 to risperidone in behavior 
problems. However, these results have not been verified in 
any other study.
Aripiprazole is the other FDA-approved atypical antip-
sychotic for use with children and adolescents with ASD.30,31 
There have been two RCTs demonstrating the efficacy 
of aripiprazole in reducing irritability, hyperactivity, and 
 stereotypies.32–34 The effect on irritability was sustained in 
an open-label follow-up trial of the above studies.35 Efficacy 
has also been demonstrated in another recent open-label36 
study and a retrospective study.37 However, aripiprazole is not 
without side effects, which includes weight gain, sedation, 
sialorrhea, and EPS.30–34
There are only case reports documenting the use of 
clozapine in children and adolescents with ASD. Only one 
case report was published recently, on a 15-year-old girl with 
ASD, who previously failed treatment with  risperidone and 
haloperidol. Her aggressive behavior  dramatically improved 
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with clozapine.38 However, the risk of agranulocytosis limits 
the use of clozapine.
Paliperidone, the active metabolite of risperidone, has 
been found to be generally well-tolerated and effective in 
the treatment in adolescents and young adults with ASD, 
but more research is still needed. It may have an advantage 
over risperidone in children with hepatic impairment, but 
paliperidone still shares a similar adverse effect profile as 
risperidone.17 Currently, published studies on the use of 
paliperidone in ASD are limited to an open-label trial39 and 
a few case reports.40,41 According to a recent open-label trial, 
side effects included weight gain, increased appetite, tired-
ness, EPS, and increased serum prolactin. In another case 
report, a 5-year-old boy with autism and severe aversion to 
oral medication was successfully treated with paliperidone 
palmitate given intramuscularly.41
There have been no recent published studies on the use 
of asenapine, sertindole, iloperidone, or amisulpride.
Antidepressants
Previous trials have suggested that children and adoles-
cents with ASD showed improvements with fluoxetine.42,43 
More recently, a double-blind placebo-controlled trial with 
fluoxetine in adult patients reported significant improve-
ment in their obsessive-compulsive symptoms and overall 
symptoms.44 Although older trials did not find fluvoxamine 
to be effective in younger patients with ASD, a randomized 
double-blind placebo-controlled crossover study reported 
that fluvoxamine was helpful in treating young patients, 
and found response to be related to polymorphism within a 
serotonin transporter gene.45 Improvements in anxiety, mood, 
and irritability have been suggested in studies on citalopram46 
and escitalopram.47
In a recent meta-analysis of both published and unpub-
lished randomized double-blind placebo-controlled trials 
examining the use of selective serotonin reuptake inhibitor 
(SSRI) in ASD, Carrasco et al48 reported a significant publica-
tion bias (ie, trials with positive results were more likely to be 
published). They found that although there was a significant 
treatment effect of SSRI (used for treating repetitive behav-
iors in ASD), these findings did not persist after they statisti-
cally adjusted for the publication bias. Meta-regression did 
not demonstrate a significant effect of SSRI treatment with 
age, although the trend among trials revealed that increased 
average patient age was associated with a greater treatment 
effect.48 A Cochrane review examined RCTs that studied 
the efficacy of several SSRIs (fluoxetine, fluvoxamine, 
 fenfluramine, and citalopram) in treating ASD and reported 
that there was no evidence that SSRIs improved ASD symp-
toms, adding that it may even possibly cause harm.49
Clomipramine, with its SSRI properties and efficacy 
in treating obsessive compulsive disorder (OCD), is the 
most-studied tricyclic antidepressant. Previous double-blind 
trials suggested that clomipramine improved ASD symp-
toms, anger outbursts, repetitive behavior, hyperactivity, 
and irritability.50,51 In a Cochrane review on the efficacy of 
tricyclic antidepressants in treating ASD, three RCTs were 
examined.52  Clomipramine appeared to improve ASD symp-
toms, irritability, and OCD-type symptoms, but its effect on 
hyperactivity was not consistent.
Overall, the role of antidepressants remains unclear, and 
more research is needed. Children and adolescents with 
ASD appear to experience significant side effects, such as 
 behavioral activation (hyperactivity and agitation), aggres-
sion, and suicidal ideation,53 all of which can limit its use.
Mood stabilizers/antiepileptics
A study found that divalproex was helpful for symptoms of 
irritability/aggression in children and adolescents with ASD,54 
while findings in earlier studies were inconsistent.55,56
Findings on levetiracetam have been inconsistent, 
with an open-label study showing improved symptoms of 
 aggression, impulsivity, hyperkinesis, and mood instabil-
ity,57 while another, more recent placebo-controlled study 
reported no improvement in the behavioral problems associ-
ated with ASD.58
There have been no other recent positive findings for this 
class of medication and its use in ASD. However, it should 
be noted that this class of medication has significant side 
effects that limit its use in this population.
Medications for ADHD
MPH is a stimulant, which has been used in children with ASD 
and comorbid ADHD symptoms. However, its efficacy has 
been limited, due to the adverse side effects commonly reported 
in children with ASD, in comparison to children with ADHD 
alone.59,60 An earlier review suggested that MPH was superior 
to the placebo, but the response rate was low, and the side 
effects were prominent in children with ASD.61 This suggests 
that MPH is not as efficacious in ASD as it is for ADHD.
Recently, there has been a slight shift to what was 
 previously found, as few studies have started to report 
positive results with MPH in children with ASD. A study of 
20 preschool children aged 3–5 years old with developmen-
tal disorders showed an improvement in the parents’ rating 
of ADHD symptoms, although adverse events were more 





common.62 Another recent study also reported positive results 
with MPH on social communication and self-regulation in 
children with ASD and hyperactivity.63
Although MPH has been associated with more adverse 
events in children with ASD, a number of trials suggested 
beneficial results in children with ASD.65 Three RCTs have 
reported improvement of ADHD symptoms in children 
with ASD.66–67
Atomoxetine is a selective norepinephrine reuptake inhibi-
tor, which is approved by the US FDA for the treatment of 
ADHD. It is a nonstimulant and, therefore, may offer better 
tolerability compared to MPH.68 A recent review on atom-
oxetine suggested that its efficacy was most noticeable in 
individuals with a low severity of ASD.69 Additionally, in a 
10-week open-label study of 12 children with a high severity 
of ASD and symptoms of ADHD, results suggested that the 
participants did not benefit from atomoxetine and were more 
vulnerable to the adverse effects.70 On the contrary, a num-
ber of studies have suggested beneficial results on ADHD 
symptoms with atomoxetine in children with ASD. A recent 
open-label study showed improvement in ADHD symptoms 
and fewer adverse effects in individuals with ASD who also 
met criteria for ADHD.71 A recent double-blind placebo-
controlled 8-week trial demonstrated the superior efficacy 
of atomoxetine compared to placebo on ADHD symp-
toms of children and adolescents with ASD.  Additionally, 
improvements in ADHD symptoms were still observed after 
28 weeks.72  Several other studies have demonstrated improve-
ments of ADHD symptoms with atomoxetine in children and 
adolescents with ASD.73–76 In a 10-week open-label study, 
positive results with atomoxetine were also reported in high-
functioning boys with ASD and comorbid ADHD.77
Guanfacine and clonidine (both alpha-2 adrenergic agonists) 
have been used in the treatment of ADHD. Contrary to clonidine, 
guanfacine has a longer half-life, which allows for lower dos-
ing. In addition, it has fewer sedative effects. In earlier trials, 
guanfacine has been found to be effective in the ASD population 
in reducing hyperactivity, inattention, and impulsivity.78–80 Clo-
nidine is an FDA-approved medication, used as an adjunction 
medication in the traditional treatment of ADHD.81 In previously 
published double-blind trials, clonidine was reported to reduce 
irritability, hyperactivity, and impulsivity.82,83 However, the lack 
of current research in this area limits the conclusions that can 
be drawn for the use of clonidine in treating ASD.
Novel treatments
The quest to develop drugs to effectively target socialization 
and communication in ASD has been challenging. Factors 
contributing to this difficulty include the lack of specific 
understanding of the neurobiology of ASD, the  heterogeneity 
of the condition, and the natural course of gradual improve-
ment in these core symptoms over time. However, a number 
of drugs are beginning to show promise in the area and 
deserve further study.84 Recent studies have also focused on 
medications traditionally regarded as complementary agents, 
suggesting potential benefits. These medications offer novel 
options to the practicing clinician in the management of the 
ASD population and, hence, have been presented in more 
detail.
Melatonin
An endogenous neurohormone, melatonin is secreted by the 
pineal gland, causing drowsiness. Melatonin levels increase 
rapidly after nightfall, peak in the middle of the night, and 
decrease toward dawn. Melatonin has been increasingly used 
to manage sleep disorders in children with ASD. In the last 
5 years, various retrospective studies, open-label trials, and 
placebo-controlled trials have been conducted.
In a retrospective study on 107 children (aged 2–18 years 
old) with ASD, 85% of parents reported partial or full 
improvement in sleep.85 Another case series studied six 
adults with ASD on melatonin retrospectively and reported 
improvements in long sleep latency, night waking, and set-
tling difficulties.86 A recent open-label trial87 studied mela-
tonin in 24 children with ASD over a 14-week intervention. 
Supplemental melatonin improved sleep latency in most 
children at 1 or 3 mg doses, within 1 week of treatment.
Small RCTs with melatonin have also shown promise. In 
a randomized, double-blind crossover trial in 18 children with 
ASD (n=8) and/or Fragile X syndrome, there was a significant 
increase in total sleep time and decrease in sleep latency 
in melatonin compared to placebo.88 Another randomized, 
double-blind crossover trial was conducted on 22 children and 
adolescents with ASD involving 3 months of placebo and 3 
months of melatonin. Melatonin significantly improved sleep 
latency and total sleep, and the side effect profile was low.89 
In addition, a randomized placebo-controlled trial examining 
insomnia in children with ASD was conducted. In their study, 
they compared melatonin alone, melatonin combined with 
cognitive behavioral therapy, cognitive-behavioral therapy 
and placebo in children with ASD.90 Findings suggested 
that adding behavioral intervention to melatonin treatment, 
resulted in better treatment response, at least in the short 
term.
Melatonin appears to have potential in the treatment of 
sleep problems in ASD, although larger trials are needed.




Drugs in development for ASD
Omega-3 fatty acids
A group of polyunsaturated fatty acids, the three main types 
found in the human diet are ALA (alpha-linolenic acid), DHA 
(docosahexaenoic acid), and EPA (eicosapentaenoic acid). 
DHA and EPA are found in seafood, while ALA is found 
in nut and plant oils. While the human body can synthesize 
both DHA and EPA from ALA, it cannot synthesize any of 
these fatty acids from scratch. Thus, these substances are 
called “essential fatty acids.” Neural tissue contains high 
concentrations of DHA, and studies suggest that this fatty 
acid is essential to the growth and functional development 
of the brain.91 Several studies have also reported low levels 
of omega-3 fatty acids in children with ASD compared 
to controls.92 The RCTs of omega-3 supplementation have 
been conducted for the treatment of ADHD, depression, and 
schizophrenia.93
A recent Cochrane review was done on omega-3 fatty 
acids supplementation for ASD in 2011.93 In the review, 
the authors highlighted two studies in which children who 
were diagnosed with ASD were randomized into groups 
that received either omega-3 fatty acid supplementation or 
a placebo. Overall, there was no evidence that the omega-3 
supplementation had an effect on social interaction, com-
munication, stereotypy, or hyperactivity. The largest positive 
effect for treatment was reported for hyperactivity. However, 
since the sample size was small, the findings may not have 
been sufficient to provide robust evidence. Larger clinical 
trials are currently ongoing, and the results would lend bet-
ter clarity.
Glutamate receptor-related medications
Glutamate, the main excitatory neurotransmitter in our  central 
nervous system, has been implicated in ASD.  Glutamate is 
converted to gamma-amino butyric acid (GABA) in the 
brain by the glutamic acid decarboxylase protein. Related 
epigenetic factors involving GABA receptor genes have been 
associated with ASD.94 Studies that have been initially per-
formed suggest that GABA-signaling pathways are associated 
with stereotypies in a large proportion of experimental animal 
models for ASD, including Fragile X syndrome.95–97 Simi-
larly, there are reports suggesting associations between ASD 
and gene variations for glutamate receptors and  glutamate 
transporter proteins.98,99
In one study in humans, the GABA type A receptors were 
found to be reduced in three brain sites which were possibly 
linked with the development of ASD, leading to the sug-
gestion of extensive GABAergic dysfunctions in the brains 
of individuals with ASD.100 The plasma levels of glutamate 
and glutamine were found to be high in children with high-
functioning ASD,101 leading to the postulation that the plasma 
levels of glutamate and glutamine could serve as early 
markers of glutamatergic dysfunction in ASD. In addition, 
an increased GABA level in the plasma of  individuals with 
ASD has also been found.102 In another study, an abnormal-
ity in the proportion of GABA to the glutamate level in the 
brains of individuals with ASD has also been suggested.103 
A recent review paper by Essa et al suggested that excessive 
glutamatergic activity might cause excitotoxicity in the brain 
that might result in the abnormal development of neurons 
leading to ASD.104
Various medications that work within the glutamatergic 
system, including at the N-methyl-D-aspartate (NMDA) 
subtype of the glutamate receptor, have been studied for their 
roles in treating ASD and the related symptoms.  Glutamate 
antagonists work by blocking the glutamate receptor and 
moderating excessive excitation at the neuronal level. In 
one animal model, a glutamate antagonist, 2-methyl-6-
(phenylethynyl)pyridine (MPEP) was studied in relation to 
autism. Although the authors have suggested that metabotro-
pic glutamate receptor 5 (mGluR5) antagonism might be 
effective in the treatment of stereotypic behaviors, the MPEP 
might have adverse effects on the core symptoms of ASD 
(sociability). It was further postulated that the MPEP’s effects 
appeared to be complex and inconsistent, which could have 
resulted in improvements in some aspects of sociability but 
worsening in others.105,106 In a recently published animal 
model study using D-cycloserine, an NMDA-receptor ago-
nist, the authors suggested that there were improvements in 
social behavior when used concurrently with social behav-
ioral therapy. In addition, it was postulated that glutamate 
transmission might have a role in the development of social 
bonds in animals and that D-cycloserine enhances the assimi-
lation of social information.107
Studies have also moved toward investigating glutamate 
receptor-related medications in clinical populations. In a 
double-blind clinical trial by Lemonnier et al, the diuretic, 
chloride-importer antagonist bumetanide, which reduces 
intracellular chloride and enhances GABAergic inhibition, 
was studied.108 In this study, bumetanide showed signifi-
cant improvements in the Childhood Autism Rating Scale, 
and Clinical Global Impressions and Autism Diagnostic 
 Observation Schedule after eliminating the most severe 
cases. Side effects of mild hypokalemia were noted. As such, 
the authors went on to suggest that bumetanide could be a 
promising novel agent in treating ASD and highlighted the 
need for further extensive trials.





One of the more commonly known NMDA-receptor 
antagonists is memantine, which has been used in the 
treatment of Alzheimer’s dementia. Memantine serves as 
a moderate affinity antagonist of the NMDA receptor. In a 
retrospective open-label study of 18 patients (6–19 years of 
age) with ASD, who were treated with memantine, eleven 
out of 18 responded with improvements in social withdrawal 
and inattention.109 However, in the same study, seven out 
of 18 patients developed adverse effects, which included 
sedation, irritability, rash, emesis, and increased seizure 
frequency.
In another open-label study by Niederhofer, which stud-
ied the effects of memantine (20 mg per day for 4 weeks) 
in four children with ASD, the findings revealed significant 
improvements in irritability, hyperactivity, and inappropriate 
speech.110 Similarly, an earlier study involving individuals 
with ASD showed improvements in the areas of  hyperactivity, 
irritability, lethargy, and memory tests.111
Recently, there has been interest in the effects of com-
bining memantine with risperidone. For example, in a 
10-week, randomized double-blind, placebo-controlled trial, 
memantine combined with risperidone was prescribed to 
40 children (4–12 years of age). The results demonstrated 
significant improvements in the memantine group in terms 
of irritability, stereotypic behavior, and hyperactivity. Such a 
combination was also well-tolerated. The authors concluded 
that memantine might be a potential adjunctive treatment 
strategy for individuals with ASD.29 In an earlier open-label 
add-on therapy study involving memantine, which spanned 
across a 21-month period with individuals with autism and 
ASD, participants showed significant improvements in their 
language functioning, social, and – to a lesser degree – self-
stimulatory behaviors.112
Acamprosate, a GABA type A agonist and excitatory 
 glutamate antagonist, has also been studied in a recent 
open-label study. Erickson et al posited that it brought about 
s ignificant improvements in social withdrawal, hyperac-
tivity, Social Responsiveness Scale, and Clinical Global 
Impression–Severity scale scores.113
The literature, both in the animal and human studies, has 
suggested that glutamate abnormalities are present in animal 
models with stereotypies and in clinical populations with 
ASD. Questions remain unanswered for the specific etiologies 
resulting in abnormal glutamate levels, which can range from 
dietary origin to glutamate receptor/transporter problems. 
However, with this improved understanding of the possible 
etiology underlying this disorder, pharmacological strate-
gies targeting the glutamate receptors now show promise 
in ASD, particularly for the core symptoms of stereotypical 
and social behaviors.
Oxytocin
Recent research has suggested that the neuropeptide oxytocin 
may play a role in the etiology of ASD. Oxytocin is synthe-
sized in the magnocellular neurons in the paraventricular 
nucleus and the supraoptic nucleus of the hypothalamus. It is 
released into the bloodstream by way of the axon terminals in 
the posterior pituitary. It is released both peripherally (where 
it is involved in milk letdown and the facilitation of uterine 
contractions) and centrally, where it acts as a neuromodulator 
along with arginine vasopressin. Oxytocin (and arginine 
vasopressin) may play a neuromodulatory role in affiliative 
and sexual behaviors, separation distress, social memory and 
recognition, stress response, and the regulation of feeding and 
grooming. It has been suggested that oxytocin abnormalities 
may exist in ASD.114
Early studies investigated the effects of oxytocin infusion. 
Findings suggested that oxytocin infusions reduced repeti-
tive behaviors and improved affective speech comprehension 
from pre- to postinfusion.115,116 Recent studies have focused 
on investigating social behaviors in ASD with intranasal 
oxytocin. In a study that investigated the behavioral effects 
of oxytocin in 13 subjects with ASD, findings suggested 
that after an oxytocin infusion, subjects exhibited stronger 
interactions and increased eye gaze.117 In another single-
armed, open-label study in which oxytocin was administered 
intranasally to eight male youths with ASD, six of the eight 
participants showed improved scores on the communication 
and social interaction domains of the Autism Diagnostic 
Observation Schedule–Generic (ADOS–G). No side effects 
were noted.118
Several small randomized trials have also been done. In 
a double-blind, randomized, placebo-controlled crossover 
trial, an oxytocin nasal spray or placebo was administered 
to 16 male youths with ASD.119 In comparison with the pla-
cebo, the oxytocin administration improved performance 
on the Reading the Mind in the Eyes Task.119 Another pilot, 
 randomized, double-blind, placebo-controlled, parallel 
design trial was conducted whereby intranasal oxytocin 
was compared to placebo in 19 adults with ASD.120 Results 
also suggested improvements after 6 weeks in measures of 
social cognition. Additionally, oxytocin was reported to be 
well-tolerated.120 Finally, in another trial, intranasal oxyto-
cin was administered to 14 individuals with ASD and 14 
neurotypical control participants. They then performed a 
face-matching and a house-matching task during functional 
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magnetic resonance imaging. The study was tested in a 
randomized, placebo-controlled, within subject, crossover 
design. After oxytocin, right amygdala activity to facial 
stimuli increased in the ASD group, relative to the control 
group.121
Oxytocin shows promise as a drug targeting the core 
social and communication deficits in ASD. Further studies 
with larger sample sizes would be needed to ascertain the 
efficacy of oxytocin.
Conclusion
The current clinical practice in psychiatry focuses on the 
use of medications in ASD by targeting specific associated 
symptoms, not unlike that in the management of other mental 
health conditions. There are well-established and licensed 
antipsychotic medications for the treatment of specific 
symptoms associated with ASD. For example, risperidone 
and aripiprazole target the management of symptoms, such 
as irritability and hyperactivity. Findings from trials for other 
medications have been less consistent. For example, antide-
pressants and mood stabilizers have been reported to be asso-
ciated with tolerability issues that need to be balanced against 
possible benefits. The use of atomoxetine and stimulants 
remains positive for targeted symptoms, although the ASD 
population is potentially more vulnerable to adverse events. 
These medications, coupled with a good clinical understand-
ing of the patient’s strengths and difficulties, as well as 
functional analysis of behavior combined with psychological 
strategies, may be helpful for some persons with ASD. While 
the associated symptoms in ASD may be ameliorated, many 
of these symptoms are manifestations that stem from the core 
social communication difficulties and repetitive, restricted 
behaviors in this population. For instance, anxiety in ASD 
may result from difficulties in peer interactions or problems 
adjusting to changes in the environment. This intrinsically 
limits the benefits from traditional pharmacology as the core 
deficits in ASD are not directly addressed.
Recent research in ASD has moved toward investigating 
the etiological factors contributing to this complex spectrum 
of disorders. There is now a growing body of research on 
genetics, epigenetics, neurological abnormalities, neu-
rotransmitters, hormonal, immunological, prenatal, and 
environmental factors in ASD. For instance, some studies 
have investigated the association between immunologi-
cal factors, such as human leukocyte antigen alleles and 
ASD.122,123 Calcium channel membrane proteins, such as the 
synaptosomal-associated protein of 25 KD (SNAP 25) and 
the soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE) protein have also been implicated 
and findings suggest that polymorphisms of the SNAP25 gene 
may be linked to symptomatology in ASD.124,125 This move 
toward understanding the basis of ASD will allow a better 
conceptualization of the disorder from a biological perspec-
tive and allow more accurate definition and diagnosis. From 
a clinical perspective, this will also serve a pivotal role in 
the clinical approach to managing ASD. Pharmacologically, 
this will allow the development of medications targeting 
the biological basis of ASD, hence being more specific and 
potentially improving the core deficits of this condition. 
Much of the research in this direction is currently laboratory 
based. However, there is potential for this work to extend to 
clinical applicability. Work in glutamate and oxytocin has 
moved from genetic, epigenetic, and neuronal studies to 
animal models and, currently, to clinical trials. While find-
ings are preliminary, there are indications that there could be 
potential benefits in the social communication and repetitive 
behavioral difficulties with these medications. This calls for 
collaborative bench to bedside research between scientists 
and clinicians with a view to breaking new ground in the 
development of new drugs in the management of ASD.
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